KARDEGIC 75 mg, poudre pour solution buvable en sachet-dose, CLOPIDOGREL, CLOPIDOGREL
Etude DAPT-CTO
Phase 3 small_molecule active
Quick answer
KARDEGIC 75 mg, poudre pour solution buvable en sachet-dose, CLOPIDOGREL, CLOPIDOGREL for chronically occluded coronary artery is a Phase 3 program (small_molecule) at ISTA Pharma Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ISTA Pharma Limited
- Indication
- chronically occluded coronary artery
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active